Pre-eclampsia Risk in Women Pregnant After Oocyte Donation
Follows pregnant women to study pre-eclampsia after donated-egg and own-egg fertility treatment.
Plain-language title generated from the registry record
Registry title: PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)
Key facts
- Where
- Copenhagen, Hellerup, Herlev, København Ø, København S, and Søborg, DenmarkSee the 6 sites
Where in Denmark
- Copenhagen Fertility CenterCopenhagen, DenmarkTaking people
- Trianglen Fertility ClinicHellerup, DenmarkTaking people
- Fertility Clinic, Herlev / Gentofte HospitalHerlev, DenmarkTaking people
- Fertility Clinic, RigshospitaletKøbenhavn Ø, DenmarkTaking people
- Sellmer KlinikKøbenhavn S, DenmarkTaking people
- Aleris FertilitySøborg, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Copenhagen University Hospital, Hvidovre
- Trial code
- NCT07263490
- Record updated
- 13 April 2026
- Original description
The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.Read full original descriptionShow less
PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.
The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.
Participants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.
Inclusion: Age > 18 years; BMI < 35 kg/m2; Normal wet smear within the past three years; Both nulli- and multiparous; Singletons and multiple gestations.
Exclusion: Previous breast cancer; Present or previous chemotherapy/radiation therapy; Alcohol/drug abuse; HIV/ hepatitis; Essential hypertension; Chronic kidney disease; Undiagnosed vaginal bleeding; Unregulated thyroid disease; Cardiovascular disease; Present or previous malignant disease; Age < 18 years; BMI > 35 kg/m2; Uterine malformations; Persisting ovarian cysts; Tumors in hypothalamus, pituitary, thyroid, or adrenal glands; Known BRCA 1 or 2 gene; Breast feeding; Smoking.